Improving Symptoms.
Increasing Quality of Life

Sativex is a cannabinod based oromucosal spray approved for the management of resistant MS spasticity, having demonstrated efficacy relieving spasticity and associated symptoms, such as spasms, cramps, pain, bladder dysfunction and sleep disorders and an appropriate tolerability profile, so MS spasticity patients can better develop their daily lives.

See linked SmPC for details

Please find here more about how to help your patients

Sativex Assistance Device

The new, state of the art Sativex® assistance device is simple to use, making administration easier for MS spasticity patients with upper limb/hand impairment.

New data for moderate patients

SAVANT clinical trial sub-analysis from Dr. Meuth:

New research shows that Sativex® improves the mean MS spasticity score and pain score at week 12 compared to placebo – both in severe and moderate patients – regardless of initial EDSS, NRS score or MS spasticity duration.

Patient Support Materials

“Share with your patients on Sativex the Patient Support Kit, from titration to symptoms tracker to caregivers’ guide.


Ask the expert

Want to know more about Sativex? Click below to get in touch with Professor Tiina Rekand who will answer any questions you may have.


Sativex®  is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.


Leaving Almirallmed

You are about to leave
Thanks for your visit
Come back soon!

Informasjonen på denne websiden er kun beregnet for helsepersonell.
The information on this website is intended for healthcare professionals only.
JA, jeg bekrefter at jeg er helsepersonell
YES, I confirm that I am a
healthcare professional

NEI, jeg er ikke helsepersonell

NO, I am not a healthcare professional